70 results on '"Herbert, Andrew S."'
Search Results
2. Design and characterization of protective pan-ebolavirus and pan-filovirus bispecific antibodies
3. Crimean-Congo Hemorrhagic Fever Survivors Elicit Protective Non-Neutralizing Antibodies that Target 11 Overlapping Regions on Viral Glycoprotein GP38
4. Seroprevalence as an Indicator of Undercounting of COVID-19 Cases in a Large Well-Described Cohort
5. SARS-CoV-2 Aerosol and Intranasal Exposure Models in Ferrets
6. Author Correction: Two point mutations in protocadherin-1 disrupt hantavirus recognition and afford protection against lethal infection
7. Prophylactic Administration of the Monoclonal Antibody Adintrevimab Protects against SARS-CoV-2 in Hamster and Non-Human Primate Models of COVID-19
8. 1143. Prophylactic and Therapeutic Activity of AZD7442 (Tixagevimab/Cilgavimab) in SARS-CoV-2 Hamster Challenge Models
9. Two point mutations in protocadherin-1 disrupt Andes hantavirus recognition and afford protection against lethal infection
10. Human antibody recognizing a quaternary epitope in the Puumala virus glycoprotein provides broad protection against orthohantaviruses
11. The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans
12. Antibody Response to SARS-CoV-2 Infection and Vaccination in COVID-19-Naïve and Experienced Individuals
13. Bisindolylmaleimide IX: A novel anti-SARS-CoV2 agent targeting viral main protease 3CLpro demonstrated by virtual screening pipeline and in-vitro validation assays
14. A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants
15. Two Distinct Lysosomal Targeting Strategies Afford Trojan Horse Antibodies With Pan-Filovirus Activity
16. AZD7442 demonstrates prophylactic and therapeutic efficacy in non-human primates and extended half-life in humans
17. Characterization of an Anti-Ebola Virus Hyperimmune Globulin Derived From Convalescent Plasma
18. Heparin: A simplistic repurposing to prevent SARS-CoV-2 transmission in light of its in-vitro nanomolar efficacy
19. A combination of RBD and NTD neutralizing antibodies limits the generation of SARS-CoV-2 spike neutralization-escape mutants
20. Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes
21. Protective neutralizing antibodies from human survivors of Crimean-Congo hemorrhagic fever
22. Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody
23. An Engineered Antibody with Broad Protective Efficacy in Murine Models of SARS and COVID-19
24. Bisindolylmaleimide IX: A novel anti-SARS-CoV2 agent targeting viral main protease 3CLpro demonstrated by virtual screening and in vitro assays
25. Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2
26. A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition
27. Bisindolylmaleimide IX: A novel anti-SARS-CoV2 agent targeting viral main protease 3CLpro demonstrated by virtual screening and in vitro assays
28. Broad neutralization of SARS-related viruses by human monoclonal antibodies
29. Neutralizing Antibodies against Crimean–Congo Hemorrhagic Fever Virus Derived from a Human Survivor
30. Animal Model Prescreening: Pre-exposure to SARS-CoV-2 impacts responses in the NHP model
31. Mapping the Interface between New World Hantaviruses and Their Receptor, PCDH1
32. A replication-competent vesicular stomatitis virus for studies of SARS-CoV-2 spike-mediated cell entry and its inhibition
33. Broad sarbecovirus neutralizing antibodies define a key site of vulnerability on the SARS-CoV-2 spike protein
34. Development of an antibody cocktail for treatment of Sudan virus infection
35. Multiple viral proteins and immune response pathways act to generate robust long-term immunity in Sudan virus survivors
36. Structural basis of broad ebolavirus neutralization by a human survivor antibody
37. A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates
38. Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-Ebolavirus Protection
39. Protocadherin-1 is essential for cell entry by New World hantaviruses
40. Human antibody cocktail deploys multiple functions to confer pan-ebolavirus protection
41. Two-antibody pan-ebolavirus cocktail confers broad therapeutic protection in ferrets and nonhuman primates
42. Structural Basis of Broad Ebolavirus Neutralization by a Human Survivor Antibody
43. A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus
44. Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection
45. NRP2 and CD63 Are Host Factors for Lujo Virus Cell Entry
46. Vesicular Stomatitis Virus Pseudotyped with Ebola Virus Glycoprotein Serves as a Protective, Noninfectious Vaccine against Ebola Virus Challenge in Mice
47. Marburg virus survivor immune responses are Th1 skewed with limited neutralizing antibody responses
48. Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses
49. Longitudinal peripheral blood transcriptional analysis of a patient with severe Ebola virus disease
50. Cooperativity Enables Non-neutralizing Antibodies to Neutralize Ebolavirus
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.